3,110 件 ・ 関連度順
概要と使いどころ
Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.
日本語の概要は準備中です。原文の説明を表示しています。
Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).
日本語の概要は準備中です。原文の説明を表示しています。
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
Statistical modeling — linear/logistic/ordinal/Poisson regression, ANOVA, Kruskal-Wallis, chi-square, Mann-Whitney, Cox survival, spline fits (R `ns()`), odds ratios, Cohen's d, F-statistic, p-value computation. Specializes in clinical-trial AE analysis (SDTM DM/AE), severity ordinal regression, and per-feature stat workflows.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
Diagnostic test / biomarker accuracy — sensitivity, specificity, PPV, NPV, likelihood ratios, accuracy from a 2x2 table; ROC curve, AUC, and the optimal cutoff (Youden) for a continuous biomarker; and post-test probability via Bayes. Use when you have test results vs a gold standard (binary 2x2, or a continuous score + true labels) and need to judge how good the test is, pick a threshold, or compute the probability of disease given a result. Emphasizes the prevalence-dependence of PPV/NPV.
日本語の概要は準備中です。原文の説明を表示しています。
Performs time-to-event analysis for clinical trials including Cox proportional hazards regression with PH diagnostics, restricted mean survival time (RMST) under non-PH, competing risks via Fine-Gray vs cause-specific Cox, weighted log-rank and MaxCombo for non-proportional hazards, recurrent events (Andersen-Gill, PWP, WLW), and interval-censored data. Use when analyzing time-to-event endpoints (OS, PFS, DOR, TTR, TTNT) in oncology or other clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Reads, validates, and prepares CDISC SDTM and ADaM clinical trial data for analysis. Covers SDTM domain joins (DM, AE, EX, VS, LB, DS), ADaM architecture (ADSL, BDS, OCCDS, ADTTE) with traceability, treatment-emergent AE conventions, baseline derivation, SUPPQUAL/NSV handling, Define-XML 2.1, and Pinnacle 21 / CORE validation. Use when working with clinical trial datasets in CDISC SDTM/ADaM format, preparing analysis-ready data, or validating for regulatory submission.
日本語の概要は準備中です。原文の説明を表示しています。
Performs subgroup and heterogeneous treatment effect (HTE) analyses for clinical trials. Covers Mantel-Haenszel pooling, Breslow-Day, interaction tests in regression, RERI for additive interaction, modern data-adaptive HTE methods (STEPP, SIDES, causal forests, X/R-learners), Bayesian shrinkage (Dixon-Simon, MAP, EXNEX), graphical multiplicity (Bretz-Maurer), and credibility frameworks (Sun BMJ, EMA 2019). Use when analyzing treatment effects across patient subgroups for regulatory submissions or precision-medicine claims.
日本語の概要は準備中です。原文の説明を表示しています。
Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.
日本語の概要は準備中です。原文の説明を表示しています。
Builds and validates predictive time-to-event models on clinical and omics data with penalized Cox, random survival forests, gradient-boosted and deep survival models, and prediction-grade evaluation (Uno's C, time-dependent AUC, integrated Brier, calibration, competing risks). Use when building an individualized risk predictor or prognostic omics signature, choosing a survival model, or evaluating one beyond the C-index. For Kaplan-Meier, log-rank, and classical Cox hazard-ratio inference in a trial see clinical-biostatistics/survival-analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Validates predictive models on omics and biomedical data with nested cross-validation, group/batch/temporal-aware splits, the full data-leakage taxonomy, probability calibration, decision-curve net benefit, optimism correction, sample-size planning, and TRIPOD+AI reporting. Use when estimating model performance honestly, choosing a CV scheme, detecting leakage, or judging whether reported discrimination means the model is actually useful. For feature selection itself see machine-learning/biomarker-discovery; for confirmatory-trial inference see clinical-biostatistics/trial-reporting.
日本語の概要は準備中です。原文の説明を表示しています。
Generate the success criteria for a task or question, then review work against them. Given a task, goal, or open-ended question, decompose it into scenarios, evaluation perspectives, and fine-grained weighted YES/NO criteria using the Recursive Expansion Tree (RET) method; if work is supplied, score it criterion-by-criterion and surface what is missing or could be better. Use when asked to self-review or check your own work, judge whether a task is done well or completely, build a definition-of-done or completeness checklist, create an evaluation rubric or grading criteria, score or grade answers to a question, set up an LLM-as-judge rubric, or when the user mentions self-review, completeness check, success criteria, evaluation criteria, scoring rubric, Qworld, or the RET algorithm.
日本語の概要は準備中です。原文の説明を表示しています。
Performs ML-based protein-ligand pose prediction and scoring using DiffDock-L (diffusion-based), Boltz-1 / Boltz-2 (foundation model with affinity), Chai-1, AlphaFold3 ligand, EquiBind, TANKBind, NeuralPLexer, and hybrid workflows (DiffDock pose + GNINA rescore + PoseBusters QC). Explicit handling of when ML beats classical docking, when classical beats ML, the PB-invalid pose problem, and rescoring as the standard production hybrid. Use when modern docking is needed: foundation-model ligand-pose prediction, AI rescoring of classical poses, or scaffold-hopping in cross-docking scenarios.
日本語の概要は準備中です。原文の説明を表示しています。
Build agency portfolios. TRIGGERS - Use when user needs help with agency-portfolio-builder related tasks.
日本語の概要は準備中です。原文の説明を表示しています。
Installs Scenic, the probabilistic scenario description language, for the CARLA in use — pip installing it into the same interpreter that holds the CARLA client, optionally cloning the upstream repo for the example scenarios the wheel does not ship, and verifying that the `scenic` CLI, the client and Scenic's version-keyed blueprint table all agree. Use when the user asks to "install Scenic", "set up Scenic", "download Scenic", "pip install scenic", wants to run `.scenic` files, or has a Scenic whose model import or blueprint lookup fails.
日本語の概要は準備中です。原文の説明を表示しています。
Runs a single ScenarioRunner Python scenario (or a whole group) against a running CARLA server — FollowLeadingVehicle, ControlLoss, DynamicObjectCrossing, SignalizedJunctionLeftTurn and the rest of srunner/examples — in sync or async mode, with result output, recording and manual/agent control of the ego. Lists what is runnable on the checked-out branch and on the loaded map. Use when the user asks to "run a scenario", "test FollowLeadingVehicle", "list scenarios", "run a CARLA traffic scenario", or reports a scenario that is "not supported".
日本語の概要は準備中です。原文の説明を表示しています。
Runs standard-format scenarios through ScenarioRunner — ASAM OpenSCENARIO 1.x (.xosc, via --openscenario, with catalogs and ParameterDeclaration overrides) and OpenSCENARIO 2.0 (.osc, via --openscenario2, the ANTLR/osc2 pipeline). Validates a file against the schema before running, lists the bundled examples, and reports which OSC features ScenarioRunner actually implements. Use when the user asks to "run an xosc", "run an OpenSCENARIO file", "use the OpenSCENARIO standard", "run a .osc / OSC2 scenario", or hands over a scenario file from another tool.
日本語の概要は準備中です。原文の説明を表示しています。
Creates and edits CARLA Leaderboard route files — placing waypoints and scenario trigger points interactively from the spectator camera (route_creator, scenario_creator), visualising an existing route in the simulator (route_displayer), summarising it as a table (route_summarizer), capturing the current weather in route format (weather_creator), sorting scenarios by route position (scenario_orderer) and converting 1.0-format routes to 2.x (route_bridge). Use when the user asks to "make a new route", "add a scenario to a route", "visualise/debug a route", "see what's in this route file", or "convert old leaderboard routes".
日本語の概要は準備中です。原文の説明を表示しています。
Installs CARLA's ScenarioRunner (the official scenario engine) and picks the branch that matches the CARLA in use — master for 0.9.14-0.9.16 (UE4), ue5-master for 0.10.0 (UE5), leaderboard-1.0/2.0/2.1 when driving the Leaderboard. Clones or checks out the branch, installs requirements, wires PYTHONPATH (including the `agents` package the carla wheel does not ship), and verifies the import. Use when the user asks to "install scenario runner", "set up SR", "run CARLA scenarios", "use OpenSCENARIO", or has a scenario_runner that fails to import.
日本語の概要は準備中です。原文の説明を表示しています。
Turn public agenda, news, policy moves, geopolitical developments, sanctions, trade disputes, regulation, elections, diplomatic signals, and strategic-risk events into decision-ready briefs. Use when the user asks an agent to analyze what changed, why it matters, who is affected, what is uncertain, scenarios, watch-next indicators, or risk implications instead of producing a simple news summary.
日本語の概要は準備中です。原文の説明を表示しています。
Avalia qualidade UX de um projeto comparando screenshots reais contra a Design Library (24 solucoes + design system). Captura telas via Playwright, pontua aderencia a tokens/patterns, identifica desvios. Produz UX Compliance Report.
日本語の概要は準備中です。原文の説明を表示しています。